---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018267"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:34:44.395422+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bioAffinity receives US patent allowance for AI-driven lung cancer diagnostic

## Summary
- USPTO allowed patent covering AI-built algorithm and flow cytometry platform for CyPath Lung test.
- Patent titled 'Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning'.
- CyPath Lung uses TCPP porphyrin and AI to detect lung cancer in sputum; clinical results: 92% sensitivity, 87% specificity, 88% accuracy.
- Global patent estate now includes 18 awarded and 33 pending patents across 12 countries.
- Diagnostic aims to detect early-stage lung cancer (Stage 1A) noninvasively, potentially curative.

## SEC filing metadata
- accession: 0001493152-25-018267
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225018267/0001493152-25-018267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225018267/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018267
- JSON: https://secwatch.observer/filing/0001493152-25-018267.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.